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ABSTRACT 
Objective: Obstructive sleep apnea (OSA) is an increasing yet under-recognized risk factor for 
acute coronary syndrome (ACS). We sought to determine the effects of ethnicity on the 
prevalence of OSA in patients presenting with ACS who participated in an overnight sleep study.  
Methods: A pooled analysis using patient-level data from the ISAACC Trial and Sleep and Stent 
Study was performed. Using the same portable diagnostic device and scoring criteria, OSA was 
defined as an apnea-hypopnea index of  ≥15. 
Results: A total of 1961 patients were analyzed, including Spanish (53.6%, n=1050), Chinese 
(25.5%, n=500), Indian (12.0%, n=235), Malay (6.1%, n=119), Brazilian (1.7%, n=34) and 
Burmese (1.2%, n=23) populations. Significant differences in body mass index (BMI) were 
found among the various ethnic groups, averaging from 25.3 kg/m2 for Indians and 25.4 kg/m2 
for Chinese to 28.6 kg/m2 for Spaniards. The prevalence of OSA was highest in the Spanish 
(63.1%), followed by the Chinese (50.2%), Malay (47.9%), Burmese (43.5%), Brazilian (41.2%), 
and Indian patients. The estimated odds ratio of BMI on OSA was highest in the Chinese 
population (1.17; 95% confidence interval: 1.10–1.24), but was not significant in the Spanish, 
Burmese or Brazilian populations. The area under the curve (AUC) for the Asian patients 
(ranging from 0.6365 to 0.6692) was higher than that for the Spanish patients (0.5161). 
Conclusion: There was significant ethnic variation in the prevalence of OSA in patients with 
ACS, and the magnitude of the effect of BMI on OSA was greater in the Chinese population than 
in the Spanish patients.  
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INTRODUCTION 
Cardiovascular disease is the leading cause of mortality, accounting for over 17 million deaths 
per year worldwide (1). Acute coronary syndrome (ACS) is the most common initial presentation 
of end organ damage due to atherosclerotic cardiovascular disease. More than one million 
patients suffer from ACS every year in the USA (2). Despite state-of-the-art treatment with dual 
antiplatelet therapy, intensive lipid lowering, and early revascularization, subsequent fatal and 
non-fatal cardiovascular events occur in over 20% of the patients who survive the initial ACS 
(3,4). The residual risk of cardiovascular events underscores the need for the identification and 
treatment of non-traditional risk factors.   
 
Obstructive sleep apnea (OSA) is a prevalent but under-recognized form of sleep-disordered 
breathing (5), and has been increasingly recognized as a risk factor and prognostic marker for 
ACS (6–8). Studies have shown that 46–66% of the patients presenting with ACS have OSA 
(8,9), and untreated OSA is associated with subsequent adverse cardiac events and repeated 
revascularization (6-8). However, a comparison of the prevalence of OSA across different ethnic 
groups has been precluded by small sample sizes and the single-center nature of the studies 
conducted. It is generally believed that the effects of OSA on the cardiovascular system are 
similar in both Western and Asian countries. However, the prevalence of OSA in the general 
population may differ not only between Western and Asian countries, but also within Asia itself 
(10,11). In this regard, Asian patients have a different prevalence of obesity as well as different 
craniofacial profiles compared with Caucasians (12,13).  
 
To date, the effects of ethnicity on the prevalence of OSA in patients presenting with ACS have 
been unknown. We conducted a pooled analysis of two large-scale, multi-center studies that 
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conducted overnight sleep examinations on patients presenting with ACS: the “impact of 
continuous positive airway pressure on patients with ACS and nonsleepy OSA” (ISAACC) Trial 
(14) and the “Sleep and Stent Study” (15). This was a multi-national collaborative effort aimed at 
determining the effects of ethnicity on the prevalence of OSA in patients with ACS, and was in 
response to the recognition that OSA is a prevalent, novel and treatable cardiovascular risk factor 
by the American College of Cardiology/American Heart Association and European Society of 
Cardiology (16,17). We hypothesized that differences in the prevalence of OSA and its 
interaction with obesity would be found among the various ethnic groups. 
 
METHODS 
Study design and patient population 
This study was a combined analysis of two datasets – the ISAACC Trial and the Sleep and Stent 
Study. The details of the protocols of these two studies have been published previously (14,15). 
The ISAACC was a multi-center Spanish study designed to investigate the benefit of continuous 
airway positive pressure (CPAP) on patients with ACS and OSA. The Sleep and Stent Study is a 
multi-national study that evaluates the clinical outcomes of patients and the prevalence of OSA 
after percutaneous coronary interventions, including patients presenting with ACS. Approval for 
both studies was obtained by local ethics or institutional review boards, and informed consent 
was obtained from all patients. 
 
A combined total of 2930 patients was available from the datasets for the Sleep and Stent Study 
(1794 patients) and the ISAAC Trial (1136). Among the patients available for primary analysis, 
29 were excluded because they were over 80 years old, 518 were excluded because of elective 
percutaneous coronary interventions, 255 were excluded because of poor quality or failed sleep 
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studies, 124 were excluded because of predominantly central sleep apnea, 7 were excluded 
because of renal impairment, and 36 were excluded because of a significant amount of missing 
data. Thus, 1961 patients were eligible for the final analysis. 
 
For the analysis of the combined dataset, we included adult patients aged between 18 and 80 
years who presented with ACS. The ethnicity of each individual patient was recorded during 
enlistment into the trials. The combined exclusion criteria were all patients with known OSA 
and/or on CPAP therapy, patients with heart failure or chronic obstructive pulmonary disease 
who were on oxygen therapy, renal insufficiency (defined as estimated glomerular filtration rate 
<15 mL/min/1.73m2), hemodynamic instability requiring the insertion of an intra-aortic balloon 
pump or mechanical ventilation, pregnancy, a history of malignancy, sedated patients, or patients 
who were unable to provide consent. 
The primary objective of the study was to compare the prevalence of OSA among the various 
ethnic groups. We also evaluated the demographic and clinical risk factors for OSA, and 
investigated the impact of body mass index (BMI) on the prevalence of OSA in different ethnic 
groups. 
 
Overnight sleep study 
The sleep studies were performed using a portable diagnostic device (Embletta Gold, Natus 
Medical Inc., Canada) that has been validated against in-laboratory polysomnography (18). The 
parameters measured included airflow (nasal cannula and thermistor), respiratory movements 
(respiratory inductance plethysmography), percutaneous oxygen saturation via digital pulse 
oximetry, snoring episodes, echocardiography, and body position.  
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The apnea-hypopnea index (AHI), quantified as the total number of apneas and hypopneas per 
hour of sleep, was measured for each sleep study. Apnea was defined as a ≥90% decrease in 
airflow from baseline for ≥10 s. Apneas were further classified as obstructive or central, 
depending on the presence of respiratory-related chest wall movement. Hypopnea was defined as 
a 30–90% reduction in airflow from baseline for ≥10 s. Desaturations were defined as a decrease 
in percutaneous oxygen saturation of ≥3% in the Sleep and Stent Study and of >4% in the 
ISAACC Trial. The studies were scored according to the American Academy of Sleep Medicine 
2007 (alternative) guidelines (19). Poor quality studies were excluded from the final analysis. 
Patients with predominantly central sleep apnea were also excluded from the analysis. 
 
Statistical analyses 
Categorical variables were presented as frequencies and percentages, and continuous variables 
were described as means with standard deviations or medians with ranges/interquartile ranges. 
Differences in the characteristics between the OSA and non-OSA groups were analyzed using 
the independent sample t-test for continuous data or the χ2 test for categorical data.  
 
A bivariate analysis of the factors affecting AHI and an age-adjusted analysis of the effect of 
BMI on sleep apnea according to ethnicity were conducted using the χ2 test and logistic 
regression, respectively, the latter was carried out using effect estimates quantified on the basis 
of the odds ratio (OR) and its associated 95% confidence interval (CI). A receiver operating 
characteristic curve (ROC) analysis was performed and the area under curve (AUC) was 
estimated and compared between the ethnic groups. Further, a forest plot was generated to obtain 
a pooled estimate of the prevalence of OSA for all ethnic groups combined, assuming a random 
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effects model. All statistical analyses were carried out using STATA v. 13 (StataCorp LP, 
College Station, TX, USA), assuming a two-sided test with a 5% level of significance. 
 
RESULTS 
Baseline characteristics 
The baseline demographic and clinical characteristics of the patients are shown in Table 1. The 
study population was predominantly male (85.1%) with a mean age of 57.7 ± 10.3 years. A total 
of six ethnicities were studied during the analysis, including Spanish (53.6%, n=1050), Chinese 
(25.5%, n=500), Indian (12.0%, n=235), Malay (6.1%, n=119), Brazilian (1.7%, n=34), and 
Burmese (1.2%, n=23) populations.  
 
Significant differences in BMI were found among the various ethnic groups, averaging from 25.3 
kg/m2 for the Indian and 25.4 kg/m2 for the Chinese to 28.6 kg/m2 for the Spanish patients. 
Among the six ethnic groups, Malays appeared to have the highest prevalence of risk factors for 
coronary artery disease, predominantly smoking, hyperlipidemia, and diabetes mellitus. Malays 
and Indians also showed a general trend towards presenting with ST elevation myocardial 
infarctions (58.0% and 64.8%, respectively).  
 
The baseline angiographic and procedural characteristics are presented in Table 2. No such data 
were available for analysis from the ISAACC Trial. The left anterior descending artery was the 
culprit vessel in 52.3% of the patients, and most of the patients (85.5% of the study population) 
presented with single vessel coronary artery disease. In line with current evidence-based 
guidelines, drug eluting stents were the preferred modality of percutaneous coronary intervention 
in 77.6% of the patients.  
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The echocardiography and laboratory characteristics across the various ethnicities are presented 
in Table 3. The median left ventricular ejection fraction ranged from 50% to 57%. The Brazilians 
appeared to have the highest serum creatinine levels among the six ethnic groups, and the Malays 
and Indians had the highest serum low-density lipoprotein levels compared with the other 
ethnicities. 
 
Overnight sleep study 
The results of the sleep study are detailed in Table 4. The median overall AHI across the various 
ethnicities was 17 (interquartile range: 7–32), and was highest in the Spanish population (median 
AHI, 20; range: 8–36) and lowest amongst the Indian population (median AHI, 9; range: 4–20). 
Using AHI ≥ 15 as the cut-off, OSA was present in 55.1% of the study population. The 
prevalence of OSA was highest in the Spanish population (63.1%), and lowest amongst the 
Indian population (36.1%). Figure 1 shows the forest plot of the prevalence of OSA among the 
various ethnicities. A bivariate analysis was further conducted to investigate the predictors of 
OSA (Table 5). In addition to ethnicity, age, BMI, and hypertension were found to be predictors 
of OSA.  
 
Effect of BMI and ethnicity on OSA 
A further multivariable analysis of these significant predictors found that the effect of BMI on 
OSA differed according to ethnicity (Table 6). A significant interaction between BMI and 
ethnicity to predict OSA was observed. The age-adjusted effect of BMI on OSA was highest in 
the Chinese population with an OR of 1.17 (95% CI: 1.10–1.24), followed by 1.16 (95% CI: 
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1.05–1.28) in the Malay population, and 1.11 (95% CI: 1.02–1.20) in the Indian population. The 
effect of BMI on OSA was not as significant in the Spanish, Burmese, and Brazilian populations.  
 
An ROC analysis was performed to assess the effect of BMI on OSA according to ethnic group. 
The AUC for the Asian ethnicities was generally higher (range: 0.6365–0.6692) than that for the 
Spanish population (0.5161) (Table 7).  
 
DISCUSSION 
This is the largest study to report the effects of ethnicity on the prevalence of OSA in patients 
presenting with ACS. The main findings of this pooled analysis confirmed that OSA was 
prevalent in patients presenting with ACS, at an overall rate of 55.1%. Significant differences in 
the prevalence of OSA were found among the various ethnic groups, being highest in the Spanish 
(63.1%), followed by the Chinese (50.2%), Malay (47.9%), Burmese (43.5%), Brazilian (41.2%), 
and Indian (36.1%) patients. Other clinical predictors of OSA were old age, BMI, and 
hypertension. We also found that the effect of BMI on OSA differed between the various ethnic 
groups. The per unit increase in BMI was associated with a higher increase in the prevalence of 
OSA in the Asian than in the Spanish patients. These observational findings were particularly 
relevant because of the lack of data on the interaction between ethnicity and OSA in patients 
presenting with ACS.  
 
Epidemiological studies have reported differences in demographic profiles, clinical presentations, 
and long-term outcomes after ACS among patients from various ethnic groups (20–22). In a 
Canadian registry that included more than 62,000 patients who presented with ACS, patients of 
South Asian origin were found to be younger, more likely to be male, and more likely to have 
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diabetes mellitus and hypertension than those of European origin (21). Similarly, in a large-scale 
registry in Singapore that included over 15,000 patients who presented with ACS, patients of 
Indian origin had the highest prevalence of diabetes mellitus, hyperlipidemia, prior myocardial 
infarction, prior percutaneous coronary intervention, and prior coronary artery bypass grafting 
compared with those of Chinese and Malay origin (22). It should be noted that, while OSA has 
been increasingly recognized as a risk factor for ACS, none of the early studies on the prevalence 
of OSA in patients presenting with ACS had reported a comparison across different ethnic 
groups. 
 
Our findings have several important clinical and research implications. We found that the 
prevalence of OSA was higher in the Spanish than in the Asian patients, even though the 
proportion of male patients was smaller in the Spanish than in the Asian cohorts. This could 
probably be explained by the higher BMI and older age of the Spanish compared with the Asian 
patients. It should be highlighted that, in the aggregate and despite the variations observed, OSA 
was highly prevalent in all of the ethnic groups. Thus, the recommendation to screen for and treat 
OSA as a potential strategy to improve cardiovascular outcomes should be a global strategy 
rather than be focused on certain ethnic groups (17).  
 
Although the BMI of the Asian cohorts appeared to be lower than that of the Spanish cohort, the 
impact of BMI on OSA in Asians should not be underestimated. Indeed, the results of the present 
study indicated that the age-adjusted effect of BMI on OSA in the Chinese, Malay, and Indian 
populations was more notable than that in the Spanish cohort. The OR of the per unit increase in 
BMI on OSA was highest in the Chinese population (1.17), implying that, for every unit 
increment in BMI, the Asian population has a greater risk of developing OSA than Spanish 
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patients, in contrast with studies on non-ACS populations, in which the magnitude of the effect 
of BMI on OSA was similar among both African Americans and Caucasians (10,23). The 
mechanism linking the larger effect of BMI on OSA in Asian ethnicities is unknown, but could 
be due to body fat distribution patterns, with a predisposition for central or abdominal fat 
distribution among Asians. Increased fat deposition around the neck results in a narrower, more 
collapsible upper airway, while central obesity is associated with reduced lung volume from fat 
deposition around the chest, reducing caudal traction on the pharynx. In view of the increasing 
epidemic of obesity affecting Asian countries (24), our findings underscore the importance of an 
efficient weight management program for the prevention of OSA.   
 
The globally high prevalence of OSA reported here also highlights the impracticability of using 
in-laboratory polysomnography as a screening method for patients with ACS. It has been 
estimated that the demand exceeds the actual capacity by a factor of 10 in most countries and by 
a factor of 50 in the United Kingdom (25). A sleep study conducted in a hospital setting using a 
portable device is an inexpensive and convenient way to circumvent this problem. Such studies 
have been shown to provide diagnostic and treatment results equivalent to those of in-laboratory 
sleep studies, and they are currently covered by insurance in the USA when used for the 
diagnosis of OSA (26). According to the American Academy of Sleep Medicine, a portable 
diagnostic device is an acceptable alternative to in-laboratory polysomnography where there are 
safety concerns about housing patients who present with ACS in a sleep laboratory (27). 
 
ACS remains a vexing problem in clinical practice and presents tremendous challenges to public 
health globally. In the past two decades, much research on OSA has focused on its association 
with cardiovascular disease. As a result, the vasculopathic effects of OSA have been increasingly 
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revealed and recognized (28). Our collaborative effort to combine large databases from different 
countries has provided an insight into the potential impact of OSA in ACS patients across 
different ethnic groups. With the high risk of recurrent cardiovascular events from OSA and the 
encouraging results of CPAP treatment in attenuating cardiovascular consequences in subjects 
with OSA, the prompt recognition and management of OSA among patients should form an 
integral part of the management of ACS. 
 
Limitations 
There are several limitations to our study. This pooled analysis combined data from two separate 
databases with prospectively enrolled patients, and amalgamation of the groups introduced a risk 
of bias. Although six ethnicities were investigated, fewer patients were Burmese and Brazilian. 
This small sample size within these ethnicities might have affected analyses within these 
subgroups. The sleep studies were analyzed independently by the two study teams. Although the 
same portable device and scoring criteria were used, inter-observer variability may have 
occurred. In addition, the Chinese patients were recruited from Mainland China, Hong Kong, and 
Singapore, and the Indian patients were from India and Singapore; therefore, differences in 
environmental effects on OSA may have influenced the results of this study.  The only 
measurements of obesity available for our analysis were BMI, weight, and neck and abdominal 
circumference. More sophisticated parameters, including body fat distribution, were not 
available. Specific craniofacial measurements were not available for analysis, and this could 
potentially be one aspect for further research in the future, because most of the data on 
craniofacial variability in ethnic groups and its impact on OSA have been obtained from 
observational studies. As the ISAACC Trial and Sleep and Stent Study are ongoing, data on the 
clinical outcomes of the patients are not reported in the present study. 
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Conclusions 
The prevalence of OSA varied significantly between Spanish and Asian patients presenting with 
ACS, and also differed among the various ethnic groups within Asia. The higher prevalence of 
OSA in the Spanish patients was probably due to the higher prevalence of obesity. It should be 
noted that the effect of a per unit increase in BMI on the OR for OSA was greater in the Asian 
patients, especially the Chinese, than in the Spanish patients. The overall high prevalence of 
OSA in patients with ACS and the feasibility of using a portable diagnostic device suggest that 
the systemic screening and treatment of OSA may be a plausible way to attenuate the risk of 
subsequent adverse events after ACS. 
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Table 5. Age-adjusted effect of BMI on sleep apnoea according to ethnic group
 
Characteristics OR 95% CI p-value
Age (years) 1.01 1.004 to 1.02 0.004
Body Mass Index (kg/m2)    
 Chinese 1.17 1.10 to 1.24 < 0.001
 Malay 1.16 1.05 to 1.28 0.005
 Indian 1.11 1.02 to 1.20 0.013
 Burmese 1.05 0.88 to 1.26 0.596
 Spanish 1.01 0.99 to 1.04 0.350
 Brazilian 1.27 0.97 to 1.66 0.084
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Table 6. Area under curve (AUC) of effect of BMI on sleep apnoea (adjusted for age) according
to ethnic group
 
Ethnicity AUC 95% CI
 Chinese 0.6365 0.5901 to 0.6809
 Malay 0.6617 0.5647 to 0.7433
 Indian 0.6403 0.5752 to 0.7026
 Burmese 0.6692 0.4273 to 0.8362
 Spanish 0.5161 0.4840 to 0.5477
 Brazilian 0.6714 0.4947 to 0.8261
 
 
 
 
 
 
 
 
 
 
 
 
 



